'Dtg nrti tdf ftc' diaporamas de présentation

Dtg nrti tdf ftc - PowerPoint PPT Presentation


Comparison of INSTI vs PI

Comparison of INSTI vs PI

Comparison of INSTI vs PI. FLAMINGO GS-236-0103 ACTG A5257. FLAMINGO Study : DTG QD + 2 NRTI vs DRV/r QD + 2 NRTI. Design. Randomisation* 1 : 1 Open-label. W48. W96. > 18 years ARV-naïve HIV RNA > 1,000 c/mL Any CD4 cell count No primary resistance in RT or protease. N = 243.

By paul
(197 views)


View Dtg nrti tdf ftc PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Dtg nrti tdf ftc PowerPoint presentations. You can view or download Dtg nrti tdf ftc presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.

Recherches associées pour Dtg nrti tdf ftc
DTG + 3TC vs DTG + TDF/FTC

DTG + 3TC vs DTG + TDF/FTC

DTG + 3TC vs DTG + TDF/FTC. GEMINI. GEMINI 1 & 2 Studies : DTG + 3TC vs DTG + TDF/FTC in first-line. Design. Randomisation * 1 : 1 Double-blind. W96. N = 716. HIV+ ≥ 18 years ARV-naïve HIV RNA 1 000-500 000 c/mL No HBV co-infection No major HIV resistance mutations. N = 717.

By buckner (0 views)

Switch to TDF/FTC/RPV - SPIRIT Study

Switch to TDF/FTC/RPV - SPIRIT Study

Switch to TDF/FTC/RPV - SPIRIT Study. SPIRIT study: switch PI/r + 2 NRTI to TDF/FTC/RPV STR. Design. Randomisation 2 : 1 Open-label. TDF/FTC/RPV STR. N = 317. 476 HIV+ adults Stable PI + RTV + 2 NRTI ≥ 6 months with HIV RNA < 50 c/mL On 1 st or 2 nd regimen No prior NNRTI use

By domani (86 views)

DTG vs LPV/r (DAWNING): Efficacy  by Baseline NRTI Resistance  and Second-Line NRTI Use

DTG vs LPV/r (DAWNING): Efficacy by Baseline NRTI Resistance and Second-Line NRTI Use

DTG vs LPV/r (DAWNING): Efficacy by Baseline NRTI Resistance and Second-Line NRTI Use. Dannae Brown, 1 Ruolan Wang, 2 Mark Underwood, 2 Judy Hopking, 3 Maria Claudia Nascimento, 4 Michael Aboud, 4 Jörg Sievers 4.

By bagley (0 views)

Switch ABC/3TC pour TDF/FTC - Etude SWIFT

Switch ABC/3TC pour TDF/FTC - Etude SWIFT

Switch ABC/3TC pour TDF/FTC - Etude SWIFT. Etude SWIFT : switch ABC/3TC pour TDF/FTC. Randomisation* 1 : 1 en ouvert. S48. Schéma. TDF/FTC + IP/r (n = 155). 311 adultes VIH+ Sous ABC/3TC + IP/r ≥ 3 mois ARN VIH-1 < 200 c/ml ≥ 3 mois Pas d’antécédent de résistance aux ARV de l’étude.

By york (127 views)

Etude SPIRIT : switch pour FTC/RPV/ TDF Schéma de l’étude

Etude SPIRIT : switch pour FTC/RPV/ TDF Schéma de l’étude

Etude SPIRIT : switch pour FTC/RPV/ TDF Schéma de l’étude. CV < 50 copies/ mL sous IP + RTV + 2INTIs > 6 mois Pas de résistance génotypique c onnue aux molécules de l’étude (N = 476 traités). n = 317. FTC/RPV/TDF. FTC/RPV/TDF. 2:1. PI + RTV +2 INTIs. FTC/RPV/TDF. n = 159.

By allan (186 views)

Truvada ® for prevention Tenofovir disoproxil fumarate (TDF) + Emtricitabine (FTC)

Truvada ® for prevention Tenofovir disoproxil fumarate (TDF) + Emtricitabine (FTC)

Extracellular and Intracellular Tenofovir DF and Emtricitabine Exposure in Mucosal Tissue after a Single Dose of Fixed-Dose TDF/FTC: Implications for Pre-exposure Prophylaxis.

By mercia (469 views)

FTC

FTC

FTC. How to find the area under a curve the easy way. a = b = Find x = Find x = Set up Sum Take limit as n  ∞. An easier way is with definite integration. Evaluate the integral at the points a and b then subtract a from b to find the area.

By phuong (114 views)

ABC-3TC	N=176 	 165 	 168 TDF-FTC	N=176 	 167 	 172

ABC-3TC N=176 165 168 TDF-FTC N=176 167 172

SIMPLIFICATION WITH FI XED-DOSE TENOFOVIR-EMTRICITAINE OR ABACAVIR-LAMIVUDINE IN ADULTS WITH SUPPRESSED HIV REPLICATION (THE STEAL STUDY): A RANDOMIZED, OPEN-LABEL, 96-WEEK, NON-INFERIORITY TRIAL. P=0.98. Poster 576. FACULTY OF MEDICINE THE UNIVERSITY OF NEW SOUTH WALES

By kipling (207 views)

Étude NEAT001/ANRS143 : RAL versus TDF/FTC en 1 re ligne (1)

Étude NEAT001/ANRS143 : RAL versus TDF/FTC en 1 re ligne (1)

Étude NEAT001/ANRS143 : RAL versus TDF/FTC en 1 re ligne (1). Étude de phase III de non-infériorité , internationale multicentrique randomisée et en groupes parallèles. CROI 2014 – D'après Raffi F et al., abstract 84LB, actualisé.

By cicada (87 views)

Étude ACTG 5257 : ATV/r, RAL ou DRV/r + TDF/FTC (1)

Étude ACTG 5257 : ATV/r, RAL ou DRV/r + TDF/FTC (1)

Étude ACTG 5257 : ATV/r, RAL ou DRV/r + TDF/FTC (1). Étude d’équivalence* (efficacité virologique et tolérance) sur 96 semaines. CROI 2014 – D'après Landovitz RJ et al., abstract 85, actualisé. Critères principaux :

By xanthe (96 views)